TrialJournal of neurology2025

Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial.

Priya S Kishnani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.